These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 30762116

  • 1. Skeletal disproportion in glucocorticoid-treated boys with Duchenne muscular dystrophy.
    Kao KT, Joseph S, Capaldi N, Brown S, Di Marco M, Dunne J, Horrocks I, Shepherd S, Ahmed SF, Wong SC.
    Eur J Pediatr; 2019 May; 178(5):633-640. PubMed ID: 30762116
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Growth, bone health & ambulatory status of boys with DMD treated with daily vs. intermittent oral glucocorticoid regimen.
    Crabtree NJ, Adams JE, Padidela R, Shaw NJ, Högler W, Roper H, Hughes I, Daniel A, Mughal MZ.
    Bone; 2018 Nov; 116():181-186. PubMed ID: 30055340
    [Abstract] [Full Text] [Related]

  • 7. Feasibility of Dual Energy X-Ray Absorptiometry Based Images for Measurement of Height, Sitting Height, and Leg Length in Children.
    Capaldi N, Kao KT, MacDonald R, Grainger KC, Joseph S, Shepherd S, Mason A, Wong SC.
    J Clin Densitom; 2020 Nov; 23(3):472-481. PubMed ID: 30098887
    [Abstract] [Full Text] [Related]

  • 8. Bone mineral density and bone metabolism in Duchenne muscular dystrophy.
    Bianchi ML, Mazzanti A, Galbiati E, Saraifoger S, Dubini A, Cornelio F, Morandi L.
    Osteoporos Int; 2003 Sep; 14(9):761-7. PubMed ID: 12897980
    [Abstract] [Full Text] [Related]

  • 9. Risk factors associated with prevalent vertebral fractures in Duchenne muscular dystrophy.
    Phung K, McAdam L, Ma J, McMillan HJ, Jackowski S, Scharke M, Matzinger MA, Shenouda N, Koujok K, Jaremko JL, Smit K, Walker S, Hartigan C, Khan N, Konji VN, MacLeay L, Page M, Sykes E, Robinson ME, Alos N, Cummings EA, Ho J, Sbrocchi AM, Stein R, Saleh D, Craven BC, Dang UJ, Siminoski K, Rauch F, Ward LM.
    Osteoporos Int; 2023 Jan; 34(1):147-160. PubMed ID: 36342539
    [Abstract] [Full Text] [Related]

  • 10. Bone density and bone health alteration in boys with Duchenne Muscular Dystrophy: a prospective observational study.
    Suthar R, Reddy BVC, Malviya M, Sirari T, Attri SV, Patial A, Tageja M, Didwal G, Khandelwal NK, Saini AG, Saini L, Sahu JK, Dayal D, Sankhyan N.
    J Pediatr Endocrinol Metab; 2021 May 26; 34(5):573-581. PubMed ID: 33838091
    [Abstract] [Full Text] [Related]

  • 11. Recombinant human insulin-like growth factor-1 therapy for 6 months improves growth but not motor function in boys with Duchenne muscular dystrophy.
    Rutter MM, Wong BL, Collins JJ, Sawnani H, Taylor MD, Horn PS, Backeljauw PF.
    Muscle Nerve; 2020 May 26; 61(5):623-631. PubMed ID: 32108355
    [Abstract] [Full Text] [Related]

  • 12. Age-related changes in appendicular lean mass in males with Duchenne muscular dystrophy: A retrospective review.
    Summer SS, Wong BL, Rutter MM, Horn PS, Tian C, Rybalsky I, Shellenbarger KC, Kalkwarf HJ.
    Muscle Nerve; 2021 Feb 26; 63(2):231-238. PubMed ID: 33104257
    [Abstract] [Full Text] [Related]

  • 13. Bone Health and Endocrine Care of Boys with Duchenne Muscular Dystrophy: Data from the MD STARnet.
    Weber DR, Thomas S, Erickson SW, Fox D, Oleszek J, Pandya S, Venkatesh Y, Westfield C, Ciafaloni E, Muscular Dystrophy Tracking and Research Network (MD STAR.
    J Neuromuscul Dis; 2018 Feb 26; 5(4):497-507. PubMed ID: 30149461
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial.
    Mah JK, Clemens PR, Guglieri M, Smith EC, Finkel RS, Tulinius M, Nevo Y, Ryan MM, Webster R, Castro D, Kuntz NL, McDonald CM, Damsker JM, Schwartz BD, Mengle-Gaw LJ, Jackowski S, Stimpson G, Ridout DA, Ayyar-Gupta V, Baranello G, Manzur AY, Muntoni F, Gordish-Dressman H, Leinonen M, Ward LM, Hoffman EP, Dang UJ, NorthStar UK Network and CINRG DNHS Investigators.
    JAMA Netw Open; 2022 Jan 04; 5(1):e2144178. PubMed ID: 35076703
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness of Neridronate in the Management of Bone Loss in Patients with Duchenne Muscular Dystrophy: Results from a Pilot Study.
    Moretti A, Liguori S, Paoletta M, Gimigliano F, Iolascon G.
    Adv Ther; 2022 Jul 04; 39(7):3308-3315. PubMed ID: 35614293
    [Abstract] [Full Text] [Related]

  • 16. Cessation of ambulation results in a dramatic loss of trabecular bone density in boys with Duchenne muscular dystrophy (DMD).
    Crabtree NJ, Roper H, Shaw NJ.
    Bone; 2022 Jan 04; 154():116248. PubMed ID: 34718220
    [Abstract] [Full Text] [Related]

  • 17. The time to and determinants of first fractures in boys with Duchenne muscular dystrophy.
    Ma J, McMillan HJ, Karagüzel G, Goodin C, Wasson J, Matzinger MA, DesClouds P, Cram D, Page M, Konji VN, Lentle B, Ward LM.
    Osteoporos Int; 2017 Feb 04; 28(2):597-608. PubMed ID: 27774565
    [Abstract] [Full Text] [Related]

  • 18. Growth, pubertal development, and skeletal health in boys with Duchenne Muscular Dystrophy.
    Ward LM, Weber DR.
    Curr Opin Endocrinol Diabetes Obes; 2019 Feb 04; 26(1):39-48. PubMed ID: 30507696
    [Abstract] [Full Text] [Related]

  • 19. Use of bone age for evaluating bone density in patients with Duchenne muscular dystrophy: A preliminary report.
    Al-Zougbi A, Mathews KD, Shibli-Rahhal A.
    Muscle Nerve; 2019 Apr 04; 59(4):422-425. PubMed ID: 30636004
    [Abstract] [Full Text] [Related]

  • 20. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY, Kuntzer T, Pike M, Swan A.
    Cochrane Database Syst Rev; 2008 Jan 23; (1):CD003725. PubMed ID: 18254031
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.